Compositions for delivery of drug combinations

Details Compositions for delivery of drug combinations Compositions for delivery of drug combinations

2003-04-16

2010-12-14

Skowronek, Karlheinz R (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

Reexamination Certificate

active

07850990

ABSTRACT:
Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

REFERENCES:
patent: 4996237 (1991-02-01), Pettit et al.
patent: 5000958 (1991-03-01), Fountain et al.
patent: 5055291 (1991-10-01), Lam et al.
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5116823 (1992-05-01), Calabresi et al.
patent: 5547940 (1996-08-01), Nice et al.
patent: 5736155 (1998-04-01), Bally et al.
patent: 5795589 (1998-08-01), Mayer et al.
patent: 6214821 (2001-04-01), Daoud
patent: 6469058 (2002-10-01), Grove
patent: 6562834 (2003-05-01), Bissery
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2003/0083316 (2003-05-01), Giles et al.
patent: 2003/0147945 (2003-08-01), Tardi et al.
patent: 2004/0265368 (2004-12-01), Mayer et al.
patent: 2006/0165771 (2006-07-01), Tardi et al.
patent: 2006/0240090 (2006-10-01), Mayer et al.
patent: 2007/0148255 (2007-06-01), Tardi et al.
patent: 07277956 (1995-10-01), None
patent: WO-00/74634 (2000-12-01), None
patent: WO-03/028696 (2003-04-01), None
patent: WO-2004/093795 (2004-11-01), None
Saxon et al., Liposmal Anticancer Drugs as Agents to be Used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs, 1999, Journal of Liposome Research, vol. 9 No. 4, pp. 507-522.
Saxon et al., “Liposomal Anticancer Drugs as Agents to be Used in Combination with other Anticancer Agents: Studies on a Liposmal Formulation with Two Encapsulated Drugs”, 1999, Journal of Liposome Research, vol. 9 Issue 4, pp. 507-522. (See IDS).
Vaage et al., “Therapy of Mouse Mammary Carcinomas with Vincristine and Doxorubicin Encapsulated in Sterically Stabalized Liposomes”, 1993, International Journal of Cancer, vol. 54 Issue 6, pp. 959-964.
Bergman et al., “Synergistic Interaction between Cisplatin and Gemcitabine in Vitro”, Mar. 1996, Clinical Cancer Research, vol. 2, pp. 521-530.
Daoud et al., “Synergisitic Cytotoxic Actions of Cisplatin and Liposomal Valinomycin on Human Ovarian Carcinoma Cells”, 1991, Cancer Chemotherapy and Pharmacology, vol. 28, pp. 370-376.
Bergmann et al., “Synergistic Interaction between Cisplatin and Gemictabine in Vitro”, Mar. 1996, Clinical Cancer Research, vol. 2, pp. 521-530. (Previously submitted).
U.S. Appl. 10/406,913, filed on Apr. 2, 2003.
Final Office Action from U.S. Appl. No. 10/264,538, mailed on Dec. 27, 2006.
Amendment Under 37 CFR § 1.116 from U.S. Appl. No. 10/264,538, filed on Jul. 30, 2007.
Non-Final Office Action from U.S. Appl. No. 10/817,735, mailed on Jul. 6,2007.
Supplementary Partial European Search Report for EP 04759934.5, mailed Aug. 28, 2007, 7 pages.
Notice of Reasons for Rejection for Japanese Patent Application No. 2003-532029, mailed on Nov. 27, 2008, 2 pages.
International Search Report for PCT/US04/11812, mailed on Feb. 9, 2005, 4 pages.
Barriere et al., “Bacterial Resistence to β-Lactams, and Its Prevention with Combination Antimicrobial Therapy” Pharmacotherapy 12:397-402 (1992).
Bonner and Kozelsky, “The Significance of the Sequence of Administration of Topotecan and Etoposide” Cancer Chemother. Pharmacol. 39:109-112 (1990).
Chen et al., “Combination of All-Trans Retinoic Acid with Butyric Acid and Its Prodrugs Markedly Enhancing Differentiation of Human Acute Promyelocytic Leukemia NB4Cells” Chin. Med. Engl. 112:352-355 (1999).
Cunningham, D., “Current Status of Colorectal Cancer: CPT-11 (Irinotecan), a Therapeutic Innovation” Eur. J. Cancer 32A(Suppl. 3):S1-S8 (1996).
Daoud et al., “Synergistic Cytotoxic Actions of Cisplatin and Liposomal Valinomycin on Human Ovarian Carcinoma Cells” Cancer Chemother. Pharmacol. 28:370-376 (1991).
Engblom et al., “Additive and Supra-Additive Cytotoxicity of Cisplatin-Taxane Combinations in Ovarian Carcinoma Cell Lines” Br. J. Cancer 79:286-292 (1999).
Enzinger and Ilson, “Irinotecan in Esophageal Cancer” Oncology 14(12, Suppl. 14):26-30 (2000).
Fischel, J.-L., “Ternary Combination of Irinotecan, Fluorouracil-Folinic Acid and Oxaliplatin: Results on Human Colon Cancer Cell Lines” Brit. J. Cancer 84(4):579-585 (2001).
Frei et al., “The Relationship between High-Dose Treatment and Combination Chemotherapy: The Concept of Summation Dose Intensity” Clin. Cancer Res. 4:2027-2037 (1998).
Guichard et al., “Cellular Interactions of 5-Fluorouracil and the Camptothecin Analogue CPT-11 (Irinotecan) in a Human Colorectal Carcinoma Cell Line” Biochemical Pharmacology 55:667-676 (1998).
Hofs et al., “Concentration and Sequence Dependent Synergism of Ethyldeshydroxy-Sparsomycin in Combination with Antitumor Agents” Anticancer Drugs 5:35-42 (1994).
Kano et al., “Effects of Carboplatin in Combination with Other Anticancer Agents on Human Leukemia Cell Lines” Leukemia Research 17(2):113-119 (1993).
Kanzawa et al., “Evaluation of Synergism by a Novel Three-Dimensional Model for the Combined Action od Cisplatin and Etoposide on the Growth of a Human Small-Cell Lung-Cancer Cell Line, SBC-3” Int. J. Cancer 71(3):311-319 (1997).
Kobayashi et al., “HTCA (Human Tumor Clonogenic Assay). Probability About the Combination Use of Cisplatin and Carboplatin” Nippon Chiryo Gakkai Shi 25:2684-2692 (1990).
Kuebler et al., “Synergistic Effects of Vinblastine and Recombinant Interferon-β on Renal Tumor Cell Lines” J. Interferon Res. 10:281-291 (1990).
Langer et al., “The Role of Tegafur/Uracil in Pulmonary Malignancy” Drugs 58(Suppl.3):71-75 (1999).
Mans et al., “Sequence-Dependent Growth Inhibition and DNA Damage Formation by the Irinotecan5-Fluorouracil Combination in Human Colon Carcinoma Cell Lines” Eur. J. Cancer 35(13):1851-1861 (1999).
Massin et al., “Acute Arrhythmogenicity of First-Dose Chemotherapeutic Agents in Children” Med. Pediatr. Oncol. 39:93-98 (2002).
Saxon et al., “Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs” J. Liposome Res. 9:507-522 (1999).
Schiffelers et al., “In Vivo Synergistic Interaction of Liposome-Coencapsulated Gentamicin and Ceftazidime” J. Pharmacol. Exp. Therapeutic 298:369-375 (2001).
Schimpff, “Gram-Negative Bacteremia” Support Care Cancer 1:5-18 (1993).
Shah and Schwartz, “Cell Cycle-Mediated Drug Resistance: An Emerging Concept in Cancer Therapy” Clin. Cancer Res. 7:2168-2181 (2001).
Shih and Teicher, “Cryptophycins: A Novel Class of Potent Antimitotic Antitumor Desipeptides”.
Shlaes et al., “Emerging Antimicrobial Resistance and the Immunocompromised Host” Clin. Infect. Dis. 17:S527-S536.
Song et al., “Rapid Report. A Novel Polymeric Conjugate Carrying Two Different Anticancer Drugs” Polym. Int. 48:627-629 (1999).
Stevenson et al., “Irinotecan and UFT/Leucovorin in Patients with Advanced Cancers” Oncology 14(10, Suppl. 9):91-92 (2000).
Swaffar et al., “Combination Therapy with 5-Fluorouracil and L-Canavanine In Vitro and In Vivo Studies” Anti-Cancer Drugs 6:586-593 (1995).
Thigpen, T., “The Role of Gemcitabine-Based Doublets in the Management of Ovarian Carcinoma” Seminars in Oncology 29(1, Suppl. 1):11-16 (2002).
Todd et al., “A Follow-Up of a Randomized Study Comparing Two Chemotherapy Treatments for Advanced Diffuse Histiocytic Lymphoma” J. Clin. Oncol. 2:986-993 (1984).
Vaage et al., “Therapy of Mouse Mammary Carcinomas with Vincristine and Doxorubicin Encapsulated in Sterically Stabilized Liposomes” Int. J. Cancer 54:959-964 (1993).
Vogler, W., “High-Dose Carboplatin in the Treatment of Hematologic Malignancies”

Affiliated with

Also associated with

Rating

Compositions for delivery of drug combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for delivery of drug combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for delivery of drug combinations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4187676